Literature DB >> 25912025

Mequindox resistance and in vitro efficacy in animal-derived Escherichia coli strains.

Tao He1, Yang Wang1, Minyi Qian1, Congming Wu2.   

Abstract

This study investigated the in vitro efficacy of mequindox against enteropathogenic Escherichia coli (EPEC), and characterized the oqxAB genes as the main mequindox resistance determinant in E. coli strains of animal origin. A total of 1123 E. coli isolates were collected from domestic animals in China from the 1970s to 2013, and mequindox susceptibility was tested by broth microdilution. The percentage of E. coli isolates with increased mequindox MICs of ≥ 64 μg/ml showed a rising trend each year throughout the study period. Mequindox showed good bactericidal activity in vitro towards 20 EPEC strains, although it had a wide mutant selection window. All 1123 E. coli isolates were tested for the presence of the oqxAB genes, and the operon was detected in 322 isolates, which accounted for 94.4% (322/341) of isolates with increased MICs to mequindox (MIC ≥ 64 μg/ml). Of the isolates with mequindox MIC ≤ 32 μg/ml, 98.8% (773/782) were oqxAB negative. Polymerase chain reaction-based stability testing revealed that the IS26-oqxAB circular intermediate was present in 93.4% (309/331) of the oqxAB-positive strains, indicating that this IS26-flanked Tn6010 element was unstable and prone to excision via IS26-mediated recombination. Functional analysis of the oqxAB genes confirmed that this operon alone is sufficient to confer resistance or increased MICs to multiple antimicrobials, including mequindox. This is the first study to investigate the relationship between mequindox susceptibility and oqxAB genotype, and may provide the basis for establishing the resistance breakpoint for mequindox against E. coli.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Domestic animals; Enteropathogenic Escherichia coli; In vitro efficacy; Mequindox; oqxAB

Mesh:

Substances:

Year:  2015        PMID: 25912025     DOI: 10.1016/j.vetmic.2015.04.007

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  6 in total

1.  Virulence traits of avian pathogenic (APEC) and fecal (AFEC) E. coli isolated from broiler chickens in Algeria.

Authors:  Lounis Mohamed; Zhao Ge; Li Yuehua; Gao Yubin; Kaidi Rachid; Oumouna Mustapha; Wang Junwei; Oumouna Karine
Journal:  Trop Anim Health Prod       Date:  2017-11-21       Impact factor: 1.559

2.  Plasmid-Mediated OqxAB Is an Important Mechanism for Nitrofurantoin Resistance in Escherichia coli.

Authors:  Pak-Leung Ho; Ka-Ying Ng; Wai-U Lo; Pierra Y Law; Eileen Ling-Yi Lai; Ya Wang; Kin-Hung Chow
Journal:  Antimicrob Agents Chemother       Date:  2015-11-09       Impact factor: 5.191

3.  Characterization of oqxAB in Escherichia coli Isolates from Animals, Retail Meat, and Human Patients in Guangzhou, China.

Authors:  Jing Wang; Chan-Ping Zhi; Xiao-Jie Chen; Ze-Wen Guo; Wu-Ling Liu; Juan Luo; Xin-Yi Huang; Li Zeng; Jia-Wei Huang; Ying-Bi Xia; Meng-Ying Yi; Teng Huang; Zhen-Ling Zeng; Jian-Hua Liu
Journal:  Front Microbiol       Date:  2017-10-13       Impact factor: 5.640

Review 4.  The nature and epidemiology of OqxAB, a multidrug efflux pump.

Authors:  Jun Li; Heying Zhang; Jianan Ning; Abdul Sajid; Guyue Cheng; Zonghui Yuan; Haihong Hao
Journal:  Antimicrob Resist Infect Control       Date:  2019-02-22       Impact factor: 4.887

5.  Hybrid Atypical Enteropathogenic and Extraintestinal Escherichia coli (aEPEC/ExPEC) BA1250 Strain: A Draft Genome.

Authors:  Danielle D Munhoz; Fernanda F Santos; Thais Mitsunari; Paulo A Schüroff; Waldir P Elias; Eneas Carvalho; Roxane M F Piazza
Journal:  Pathogens       Date:  2021-04-14

6.  Novel Aminoglycoside Resistance Transposons and Transposon-Derived Circular Forms Detected in Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates.

Authors:  Nabil Karah; Chinmay Kumar Dwibedi; Karin Sjöström; Petra Edquist; Anders Johansson; Sun Nyunt Wai; Bernt Eric Uhlin
Journal:  Antimicrob Agents Chemother       Date:  2016-01-11       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.